May 2021

A research paper published in the International Journal of Biological Sciences in 2019 introduced a novel combination of Nitroxoline and PD-1 blockade to treat prostate cancer.

A murine prostate cancer orthotopic model was used for this study. The authors compared a combination therapy involving nitroxoline and PD-1 blockade with nitroxoline or PD-1 blockade alone. The research showed the combination therapy generated better results in suppressed tumor growth, reductions in tumor weight, bioluminescence tumor signals, and serum prostate-specific antigen levels.

By using fluorescence-activated cell sorting analysis, the authors found this combination therapy increased CD44+CD62L+CD8+ memory T cell numbers and reduced myeloid-derived suppressor cell numbers in peripheral blood, thus, the antitumor immunity significantly enhanced.

This research suggests that the nitroxoline and PD-1 blockade combination could be a promising treatment for prostate cancer.

Anogen’s human PSA ELISA kit was used to measure serum PSA levels in this study. This Human PSA Kit ELISA Kit is to be used for the in vitro quantitative determination of human PSA concentrations in serum and cell culture samples. PSA serum levels are elevated in patients with prostate cancer, benign prostatic hypertrophy (BPH) and inflammatory conditions associated with the tissue, so, it has been chosen as serum marker for prostate cancer screening for males over 50 years older. The authors found that the mean serum PSA level was lower in the nitroxoline plus PD-1 blockade group than in the control, nitroxoline, and PD-1 blockade groups (P < 0.05).

Figure 5. (G) Serum prostate-specific antigen levels were significantly lower in the nitroxoline plus PD-1 blockade group than in the control, nitroxoline, and PD-1 blockade groups. Data are presented as mean ± standard deviation (N = 4, *P < 0.05).

Anogen also provides high-quality monoclonal antibodies and ELISA Kits in tumor research areas, such as PD-1, PD-L1, PSA, CEA, and AFP etc.

For more information, please visit Anogen’s website: https://www.anogen.ca

Reference:

Xu, N., Huang, L., Li, X., Watanabe, M., Li, C., Xu, A., Liu, C., Li, Q., Araki, M., Wada, K., Nasu, Y., & Huang, P. (2019). The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer. International journal of biological sciences, 15(5), 919–928. https://doi.org/10.7150/ijbs.32259